Critical evaluation of the efficacy and tolerability of azilsartan. - Wikidata - awgldk - TriplyDB

Critical evaluation of the efficacy and tolerability of azilsartan.

Critical evaluation of the efficacy and tolerability of azilsartan.

http://www.wikidata.org/entity/Q38015816

about

Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry.Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study.Safety, tolerability, and efficacy of azilsartan medoxomil with or without chlorthalidone during and after 8 months of treatment for hypertension New therapeutic pathways in the RAS.Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension.An evaluation of the latest evidence relating to renin-angiotensin system inhibitors.Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?Pharmacokinetic-pharmacodynamic modeling of the antihypertensive interaction between azilsartan medoxomil and chlorthalidone in spontaneously hypertensive rats.Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin-Converting Enzyme Inhibitors: The Prospective EARLY Registry.

P2860

Q35949950-2130BA57-FD0F-48E3-B673-B79F985CDCEC Q36762587-C7DFFD55-E019-4EB4-A829-B4F9BE86FB0B Q37257463-E5F9340E-87E6-4E25-8139-1498A6E9D99E Q38061106-CA2D704A-DE1D-4E57-BBA4-6C0538382538 Q38079623-544723CB-EE8B-4581-9373-8BDCB6E74E14 Q38096442-0195A276-2A78-411E-A3AA-B2897386B6DC Q38144197-5E07AE7F-C6F5-4A05-81E4-24F6948E04D8 Q38965224-21FDD15C-A319-4D10-AFC4-22C3E32C1E8E Q40804716-14FD112E-5412-46E6-A281-722256AEC6B1

P2860

Critical evaluation of the efficacy and tolerability of azilsartan.

http://www.wikidata.org/entity/Q38015816

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Critical evaluation of the efficacy and tolerability of azilsartan.

@en

type

label

Critical evaluation of the efficacy and tolerability of azilsartan.

@en

prefLabel

Critical evaluation of the efficacy and tolerability of azilsartan.

@en

P1433

Q38015816-D0E55751-75B7-4A7D-818A-4B46BCA642AF

P1476

Q38015816-E3FF36F2-3368-401F-BB98-07EBFDABBB14

P2093

Q38015816-3AB84984-AA9C-418D-A6A5-82A410B8C1ED

Q38015816-DA76626C-E9CB-43EF-A796-71A6A01C6720

P2860

Q38015816-09F77F4B-EFA0-498A-AE19-EAE971D50F07

Q38015816-10F79F12-4D15-435F-BDF7-9AAF37FE856E

Q38015816-32609134-6135-436D-9C9E-98D38C449A69

Q38015816-34818E11-FFD4-489D-B798-E4A1D595B6E9

Q38015816-3D5B418A-459C-4448-9418-4817C925C81A

Q38015816-660AB31A-ECE1-45E5-9674-738837CD0999

Q38015816-798D720B-312F-4982-A187-580F3ADB82D1

Q38015816-7E6CB6D6-AFB5-43DD-A9F6-0273B1C51E16

Q38015816-7EFAF854-D162-4B06-984B-1A429FA41604

Q38015816-91967B90-F9AB-4FAC-BCF4-F87C0C44FE95

P304

Q38015816-4D6B1266-71DD-4359-99C9-2BE3301706BE

P31

Q38015816-8A3D1F68-F315-47C9-B6A7-E77AE018FB83

Q38015816-F73A78A0-D9AC-4B8C-A81B-365914A1F7DB

P356

Q38015816-D19AC8C6-125B-4FD0-86E9-70803F6432DF

P407

Q38015816-9275C64F-8522-475C-B75E-8E01CC15E2FB

P478

Q38015816-7DAA2744-F765-4F8D-B78E-333385E9CBF1

P50

Q38015816-0362BD93-1D15-475E-AD59-C56BC12C7D09

P577

Q38015816-230D1F75-80E9-46F8-9438-C1CAF216E847

P698

Q38015816-CFED9E78-3E53-414F-B60E-CF74DFEEE765

P921

Q38015816-173DB736-98C7-4806-A8EA-BB1EAA2BD6A6

Q38015816-57705C6A-06A0-4DC9-8C71-9FD1BC9940CA

Q38015816-C5A4D813-6FD7-4C83-BC46-F60AD42A1C5C

Q38015816-DDF61192-702D-44A5-9EB1-98848EDF88C5

P932

Q38015816-92E44B37-0BD4-4A91-98D2-FF35CB61CAEB

P356

P1433

Vascular Health and Risk Management

P1476

Critical evaluation of the efficacy and tolerability of azilsartan.

@en

P2093

Alberto R De Caterina

http://www.w3.org/2001/XMLSchema#string

Florim Cuculi

http://www.w3.org/2001/XMLSchema#string

P2860

Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension

Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk

Metabolic syndrome and kidney disease: a systematic review and meta-analysis

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Global burden of hypertension: analysis of worldwide data

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

The world health report 2002 - reducing risks, promoting healthy life

Aldosterone receptor antagonists: effective but often forgotten.

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization.

P304

299-305

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/VHRM.S22589

http://www.w3.org/2001/XMLSchema#string

P407

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Andrew R. Harper

P577

2012-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22661897

http://www.w3.org/2001/XMLSchema#string

P921

azilsartan medoxomil

mechanism of action

arterial hypertension

P932

3363145

http://www.w3.org/2001/XMLSchema#string